MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/ccid.s190473

Медицинская библиотека · Clinical, cosmetic and investigational dermatology · 2020

Sarecycline: A Review of Preclinical and Clinical Evidence.

Moore Angela Yen, Del Rosso James, Johnson Jodi L, Grada Ayman

СтатьяОбзорПеревод в очереди

Аннотация

Sarecycline is a tetracycline-derived oral antibiotic, specifically designed for acne, and is approved by the Food and Drug Administration (FDA) in 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris (AV) in patients 9 years of age and older. It has been decades since a novel systemic antibiotic was approved to treat AV, a disease that affects up to 90% of teenagers and young adults worldwide and lasts well into adulthood. Sarecycline holds promise to yield fewer side effects than other commonly used broad-spectrum tetracyclines, including minocycline and doxycycline. The narrower spectrum of antibacterial activity of sarecycline, which specifically targets C. acnes and some Gram-positive bacteria with little or no activity against Gram-negative bacteria, suggests not only the potential for reduced emergence of antibiotic-resistant bacterial strains but also less disruption of the human gut microflora. Here, we review the key preclinical and clinical evidence on sarecycline.

Для цитирования: Moore Angela Yen, Del Rosso James, Johnson Jodi L, Grada Ayman. Sarecycline: A Review of Preclinical and Clinical Evidence.. Clinical, cosmetic and investigational dermatology. 2020. DOI: 10.2147/ccid.s190473.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.